ID: ALA429079

Max Phase: Preclinical

Molecular Formula: C16H21ClN6O2

Molecular Weight: 364.84

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(Cl)cc1Nc1nc(NCCO)nc(N2CCCC2)n1

Standard InChI:  InChI=1S/C16H21ClN6O2/c1-25-13-5-4-11(17)10-12(13)19-15-20-14(18-6-9-24)21-16(22-15)23-7-2-3-8-23/h4-5,10,24H,2-3,6-9H2,1H3,(H2,18,19,20,21,22)

Standard InChI Key:  AQYDNGDNBIIYOX-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 364.84

Molecular Weight (Monoisotopic): 364.1415

AlogP: 2.28

#Rotatable Bonds: 7

Polar Surface Area: 95.43

Molecular Species: NEUTRAL

HBA: 8

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.91

CX Basic pKa: 7.47

CX LogP: 3.07

CX LogD: 2.74

Aromatic Rings: 2

Heavy Atoms: 25

QED Weighted: 0.69

Np Likeness Score: -1.58

References

1. Huang W, Zheng W, Urban DJ, Inglese J, Sidransky E, Austin CP, Thomas CJ..  (2007)  N4-phenyl modifications of N2-(2-hydroxyl)ethyl-6-(pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamines enhance glucocerebrosidase inhibition by small molecules with potential as chemical chaperones for Gaucher disease.,  17  (21): [PMID:17827006] [10.1016/j.bmcl.2007.08.050]

2. Zheng W, Padia J, Urban DJ, Jadhav A, Goker-Alpan O, Simeonov A, Goldin E, Auld D, LaMarca ME, Inglese J, Austin CP, Sidransky E..  (2007)  Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease.,  104  (32): [PMID:17670938] [10.1073/pnas.0705637104]

3. PubChem BioAssay data set, 

4. PubChem BioAssay data set, 

5. Patnaik S, Zheng W, Choi JH, Motabar O, Southall N, Westbroek W, Lea WA, Velayati A, Goldin E, Sidransky E, Leister W, Marugan JJ..  (2012)  Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase.,  55  (12): [PMID:22646221] [10.1021/jm300063b]

6. Boyd RE, Lee G, Rybczynski P, Benjamin ER, Khanna R, Wustman BA, Valenzano KJ..  (2013)  Pharmacological chaperones as therapeutics for lysosomal storage diseases.,  56  (7): [PMID:23363020] [10.1021/jm301557k]

Source

Source(2):

• Scientific Literature
• PubChem BioAssays